Barry has over thirty years of drug discovery experience working in the pharmaceutical and allied industries.  Currently focusing on a portfolio of therapeutic opportunities from King’s Health Partners, he has previously been CEO of Union Life Sciences Ltd and ReOx Ltd.  He co-founded Curidium Medica plc and was Executive Chairman taking the Company to a public listing prior to its acquisition by Avacta plc.  He has sat as non-executive director on a number of Boards and prior to these roles, Barry held senior positions in both a Biotech (De Novo Pharmaceuticals Ltd, Pharmagene Ltd) and large Pharma (Sanofi and GlaxoSmithKline) environment.